Parabilis Medicines receives buy rating and $40 target from H.C. Wainwright
PBLS•H.C. Wainwright initiated coverage of Parabilis Medicines with a buy rating and a $40 target price.
Related News
Abbott Laboratories: Wells Fargo raises target price to $119 from $112
ABT•
Federal Reserve events diary
TLT•
T1 Energy receives Commerce Department waiver for solar cell imports
TE•
Elevance Health: BofA Global Research raises price objective to $500.00 from $480.00
ELV•
Abbott: Citigroup cuts target price to $122 from $125
ABT•